Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17599354 | 0.79 | FAAH (0.33) | — | |
| SCHEMBL17599409 | 0.76 | MEN1 (0.38) | ABCG2ABCB1SLC7A5CA12CA1 | |
| SCHEMBL17613340 | 0.76 | SLC7A5 (0.42) | ABCG2ABCB1BRD4SLC7A5CA12 | |
| SCHEMBL17599347 | 0.69 | AKR1C3 (0.43) | AXL | |
| SCHEMBL17613335 | 0.68 | ABCG2 (0.37) | ABCG2ABCB1BRD4SLC7A5GRM6 | |
| SCHEMBL17599380 | 0.68 | MEN1 (0.44) | ABCG2ABCB1BRD4 | |
| SCHEMBL17599344 | 0.68 | ABCG2 (0.45) | ABCG2ABCB1BRD4SLC7A5CA12 | |
| SCHEMBL17599366 | 0.67 | KDM4E (0.41) | ABCG2ABCB1STAT3 | |
| SCHEMBL2580296 | 0.67 | PPARG (0.45) | ABCG2ABCB1BRD4 | |
| SCHEMBL1410040 | 0.67 | KMO (0.55) | ABCG2ABCB1SLC7A5CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2998294-A1 | Naphthyl sulfonamide phenyl derivatives as KEAP-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | SANOFI (FR) | 2016-03-23 | — | — | EP | disclosed |